Anthony Lucci, MD

Articles by Anthony Lucci, MD

69 The Importance of Tri-Modality Therapy for De Novo Stage IV Invasive Lobular Carcinoma (ILC) Presenting With Bone-Only Metastases

ByAttilla Soran,Berk Goktepe,Berkay Demirors,Serdar Ozbas,Efe Sezgin,Jamila Al-Azhri,Shruti Zaveri,S. Meas,Anthony Lucci, MD,Priscilla F. Mcauliffe, MD, PhD

April 21st 2024

How Heterogeneous Cell Populations, Cancer Cell Dormancy, and Minimal Residual Disease Influence the Natural History of Cancers

ByCarolyn Hall, PhD,Anthony Lucci, MD

January 15th 2011

The authors of “How Long Have I Had My Cancer, Doctor?” have addressed a question often contemplated by patients when they receive a diagnosis of cancer.

Latest Updated Articles

How Heterogeneous Cell Populations, Cancer Cell Dormancy, and Minimal Residual Disease Influence the Natural History of Cancers
January 15th 2011

Anthony Lucci, MD

Articles by Anthony Lucci, MD

69 The Importance of Tri-Modality Therapy for De Novo Stage IV Invasive Lobular Carcinoma (ILC) Presenting With Bone-Only Metastases

How Heterogeneous Cell Populations, Cancer Cell Dormancy, and Minimal Residual Disease Influence the Natural History of Cancers

Latest Updated Articles

Trending on CancerNetwork

FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma

The Lowest-Ever Hazard Ratio in Multiple Myeloma Bispecific Trials?

Why Earlier CAR T-Cell Therapy May Benefit Patients With Multiple Myeloma

Developers Initiate Phase 2/3 Ivonescimab/EV Trial in Bladder Cancer

GLP-1 Receptor Agonists and Cancer: Renewed Momentum for Metabo-Oncology